Takeda: Lymphoma trials

The registry lists 54 Lymphoma studies with Takeda as lead sponsor. 1 are open to participants now and 36 have results posted.

Phase 1 21Phase 2 16Phase 3 6Phase 4 3No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingNCT06831370Phase 4
• A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)Active, not recruitingNCT05673785Phase 2Results posted
• Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"CompletedNCT04213209Results posted
• A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin LymphomaTerminatedNCT04074330Phase 1/2Results posted
• Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"CompletedNCT03729609Results posted
• B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and OutcomesCompletedNCT03327571Results posted
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedNCT02954406Phase 1Results posted
• Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)CompletedNCT02939014Phase 2Results posted
• A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory LymphomaCompletedNCT02259010Phase 1Results posted
• Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic FunctionCompletedNCT02214147Phase 1Results posted
• Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"CompletedNCT02139592Results posted
• A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 4Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIBCompletedNCT01953783Phase 1Results posted
• A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
• Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular LymphomaCompletedNCT01939899Phase 2Results posted
• Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
• Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or LymphomasCompletedNCT01898078Phase 1Results posted
• Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of AlisertibCompletedNCT01844583Phase 1Results posted
• Mass Balance, Pharmacokinetics and Metabolism Study of AlisertibCompletedNCT01714947Phase 1Results posted
• A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaCompletedNCT01712490Phase 3Results posted
• A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)CompletedNCT01578499Phase 3Results posted
• A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasCompletedNCT01512758Phase 1Results posted
• Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin LymphomaCompletedNCT01492088Phase 1/2Results posted
• Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaCompletedNCT01482962Phase 3Results posted
• Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or LymphomaCompletedNCT01454076Phase 1Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)CompletedNCT01449461Phase 1/2Results posted
• MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- VincristineCompletedNCT01397825Phase 1/2Results posted
• Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01040871Phase 2Results posted
• Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma PatientsCompletedNCT00931918Phase 2Results posted
• A Study of IXAZOMIB in Adult Patients With LymphomaCompletedNCT00893464Phase 1Results posted
• Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With RituximabTerminatedNCT00850499Phase 2Results posted
• Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's LymphomaCompletedNCT00807495Phase 2Results posted
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00722137Phase 3Results posted
• Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular LymphomaCompletedNCT00715208Phase 2Results posted
• Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
• A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaCompletedNCT00636792Phase 2Results posted
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00312845Phase 3Results posted
• A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy AloneWithdrawnNCT06104878
• A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab VedotinCompletedNCT05886478
• A Study of People With CD30 Positive Lymphoma in ChinaCompletedNCT05506774
• A Study of Chinese Adults With LymphomaCompletedNCT05288491
• A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)CompletedNCT04887519
• A Study of Brentuximab Vedotin in Adults With CD30-positive LymphomaCompletedNCT04837222
• Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWithdrawnNCT04260009Phase 1/2
• A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian FederationCompletedNCT03942263
• Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)WithdrawnNCT03888534Phase 1
• A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) InhibitorsCompletedNCT03546894
• A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell LymphomasCompletedNCT02788916
• Study of TAK-901 in Adults With Advanced Solid Tumors or LymphomaCompletedNCT00935844Phase 1
• Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple MyelomaCompletedNCT00722488Phase 1
• Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.CompletedNCT00298779Phase 1
• VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
• VELCADE in Subjects With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00063713Phase 2
• Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell TransplantationTerminatedNCT00003056Phase 3